Claire Repellin
About Claire Repellin
Claire Repellin is a Principal Scientist at ORIC Pharmaceuticals Inc., with a strong background in molecular genetics and disease research. She has held various research positions at notable institutions, including Mayo Clinic, Dana-Farber Cancer Institute, and SRI International.
Current Role at ORIC Pharmaceuticals
Claire Repellin currently serves as a Principal Scientist at ORIC Pharmaceuticals Inc., a position she has held since 2022. In this role, she contributes to the company's research and development efforts, focusing on innovative approaches to cancer treatment. Her experience in the pharmaceutical industry supports her work in advancing therapeutic solutions.
Previous Experience at Mayo Clinic
Prior to her current role, Claire Repellin worked as a Research Fellow at Mayo Clinic from 2006 to 2010. During her four years there, she engaged in significant research projects that contributed to the understanding of molecular genetics and its applications in medicine.
Education and Expertise
Claire Repellin earned her PhD in Molecular Genetics from the University of Glasgow. She also completed a Master of Research in Molecular Functions in Disease at the same institution. Her educational background provides a strong foundation for her scientific research and expertise in the field.
Career at SRI International
Claire Repellin held multiple positions at SRI International. She worked as a Research Fellow from 2012 to 2014 and later as a Research Scientist from 2014 to 2020. Over these six years, she contributed to various research initiatives, enhancing her skills and knowledge in scientific inquiry.
Experience at Dana-Farber Cancer Institute
From 2010 to 2012, Claire Repellin was a Research Fellow at Dana-Farber Cancer Institute. Her two-year tenure involved research focused on cancer biology, furthering her experience in a leading cancer research environment.
Role at Cairn Biosciences
Claire Repellin worked as a Scientist at Cairn Biosciences from 2020 to 2022. During her two years there, she was involved in research projects aimed at developing new therapeutic strategies, contributing to the company's mission in the biosciences sector.